January 17, 2025
Hello team, Please find our social listening snapshot below for 01/07 - 01/17, along with a dashboard snapshot PDF attached.
LEO Pharma
Top LEO Pharma Company & Drug Discussions
- Company Mentions:
- LEO Pharma and Gilead Sciences partner to develop oral STAT6 therapies for chronic inflammatory diseases, including AD, asthma, and COPD, in a $1.7B deal. (Reuters, PharmaTimes, MedCity News, Fierce Pharma, BioSpace, Dermatology Times, EChemi, X)
- Financial analysts warn against potential tariffs that could impact Dernmark-based biopharmas, including LEO Pharma. (X)
- tralokinumab (ADBRY):
- The first patient is successfully enrolled into the TRAPEDS-2 trial of tralokinumab in combination with topical corticosteroids for children with moderate-to-severe AD. (X)
- A new study finds that tralokinumab administered every 4 weeks is found to be an effective maintenance dosing schedule after achieving stable disease for moderate-to-severe AD. (Dermatology Advisor, X)
- In a new Beyond the Headlines podcast, experts discuss AD’s pathogenesis, comorbidities, and when to consider biologics like tralokinumab. (X)
Other top Atopic Dermatitis (AD) & Chronic Hand Eczema (CHE) Discussions
- Mount Sinai Dermatology shares results from a recent study finding dupilumab users had a 65% lower risk of SCC/BCC than non-systemic therapy users, for severe AD. (Instagram)
- Week 16 results of the Level Up trial of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe AD are published. upadacitinib is found to be more efficacious than dupilumab when initiated at 15 mg and dose-escalated based on clinical response. (BJD, X)
- A maximum-use trial (MUsT) of ruxolitinib cream in children aged 2 to 11 years with extensive, moderate to severe AD, shows significant reductions in body surface area involvement and rapid symptom relief. (Dermatology Times)
- An HCP discusses promising results of an AD treatment that combined upadacitinib and topical corticosteroids in a webinar. (JCAD, X)
- Sanofi achieves $13B in sales of DUPIXENT in 2024, highlighting its indication for AD, presented during the annual JP Morgan Healthcare Conference. (The Pharma Letter)
- An article featuring notable drugs approvals from December 2024 is published, including the recent approvals of NEMLUVIO and VTAMA for AD. (Cardiology Advisor)
- A Long Island, NY-based dermatologist discusses new treatments for AD patients, including EBGLYSS and NEMLUVIO. (AP News Press Release)
Dr. Reddy’s Laboratories
- Company Mentions:
- Dr. Reddy’s closes its Shreveport manufacturing plant in Louisiana. (KTBS, The Advocate, Medical Dialogues, Facebook)
- Dr Reddy’s presents at the JP Morgan Healthcare Conference. (Instagram)
- denosumab:
- A new study compares denosumab to oral bisphosphonates in adults on dialysis ages 50+, finding that denosumab lowered the risk for fractures by 45% and increased the risk for MACE by 36%. (MedPage Today, ACP Journals, X, Facebook)
- An XGEVA patient shares their experience receiving injections. (Instagram)
Paratek Pharmaceuticals
- omadacycline (NUZYRA):
- In a narrative review of tetracyclines exploring pharmacological properties, clinical uses, and associated challenges, the FDA’s approval of omadacycline for CABP and ABSSSI is mentioned. (ScienceDirect, X)
Argenx
Top Argenx Company & Drug Discussions
- efgartigimod (VYVGART):
- A new post-hoc analysis of VYVGART in gMG patients with AChR autoantibodies shows sustained improvement throughout the ADAPT+ trial extension period. (AJMC)
- A phase IV study monitors interactions between VYVGART and Amlodipine, reporting issues like renal failure in females and acne in males, using AI to analyze FDA data and inform ongoing research cited in leading medical journals. (eHealthMe)
- Efgartigimod shows potential as a treatment for ocular MG, providing rapid and sustained symptom relief in two cases unresponsive to standard therapies. (Frontiers)
- efgartigimod alfa and hyaluronidase-qvfc (VYVGART Hytrulo):
- Japan’s approval of VYVDURA for CIDP continues to be covered by industry media. (BioPharma Asia, The Pharma Letter)
- An article highlights that switching CIDP treatment from IVIG to VYVGART Hytrulo involves risks of relapse, variable outcomes, and trial design issues, requiring careful, personalized strategies. (World Federation of Neurology)
- Unbranded:
- Ammie and Jose of the Caregiver’s Guide to Cancer post about their participation as hosts of the Rare, Well Done series for Shining Through CIDP. (X)
Other top Myasthenia Gravis (MG) & Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Discussions
- Alexion:
- The Unified Patent Court (UPC) Court of Appeal has upheld the Hamburg Local Division’s decisions to deny Alexion preliminary injunctions against Samsung Bioepis and Amgen for sales of biosimilars to SOLIRIS. (HGF, Law360)
- Teva Pharmaceuticals and Samsung Bioepis announce a partnership for the U.S. commercialization of EPYSQLI, a biosimilar to SOLIRIS. (LinkedIn, MSN, Teva, Business Korea)
- A phase IV study of FDA data found oropharyngeal pain as a side effect of ULTOMIRIS, especially in females aged 40-49, with less than a month of usage, often alongside SOLIRIS for MG treatment. (eHealthMe)
- AstraZeneca’s ULTOMIRIS has been reimbursed for treating atypical hemolytic uremic syndrome (aHUS) in Korea, but stringent pre-approval requirements and low reimbursement rates continue to limit access. (LinkedIn, Korea Biomedical Review)
- A case study of a thymoma-associated MG patient successfully treated with ULTOMIRIS is published. (Rare Disease Advisor, X)
- Immunovant:
- HanAll Biopharma’s U.S. partner, Immunovant, highlights its FcRn inhibitor’s unique differentiation and market leadership potential, driven by superior efficacy, dosing flexibility, and innovative autoinjector technology. (LinkedIn, Korea Biomedical Review)
- Norstella Evaluate’s “2025 Preview Report”, examining the biggest movers and shakers in biotech and pharma, mentions Immunovant and Roivant’s MG drugs—IMVT-1402 and batoclimab—as promising R&D projects to watch this year. (MM+M, Evaluate, LinkedIn)
- batoclimab is included in STAT’s Q1 2025 biotech scorecard. (STAT News)
- J&J Innovative Medicine:
- nipocalimab is granted FDA priority review for the treatment of gMG, following a successful phase 3 of the VIVACITY-MG3 trial. (Press Release, Life Science Report, X, Market Access Today, LinkedIn, MarketWatch, Applied Clinical Trials, MPR)
- An analyst mentions J&J’s nipocalimab for MG as a potential FDA approval to keep a close eye on in 2025. (PharmaVoice, Reddit)
- UCB:
- An analyst posts an engaging infographic of the best performing large pharma stocks from 2024, with UCB taking the #1 spot (100% growth) due to sales of RYSTIGGO and BIMZELX. (LinkedIn)
- Canada’s Drug Agency (CDA) posts a call for feedback regarding its draft recommendation of ZILBRYSQ for gMG. (X, Facebook)
- Other Companies and Notable Mentions:
- MGFA promotes MG Walks in the Tampa Bay Area to help raise funds for MG research and resources. (Instagram)
- A patient with MG shares their first HYQVIA infusion. (Instagram)
- A patient with MG shares their progress from prednisone side effects to stability on HIZENTRA. (Instagram)
- A phase IV study analyzes FDA data on interactions between Imuran and Detrol LA, commonly linked to MG in females and congestive heart failure in males, based on reports from 20 patients. (eHealthMe)
- Cyrus Biotechnology announces its selection of CYR212, an engineered IgG protease, as a clinical candidate for the treatment of MG. (Pipeline Review)
- A small study finds stem cell transplants effective for treatment-resistant MG. (Myasthenia Gravis News)
- A market researcher posts visual tables and charts of the current gMG competitive landscape, including approved treatments and ongoing trials from Regeneron, Immunovant, Novartis, Merck, RemeGen, Roche, UCB, argenx, and Alexion. (LinkedIn)
- Cartesian’s CAR-T trial results from December of Descartes-08 in MG patients are included in a data/trials roundup. (CGTLive)
- A new journal is published offering insights into the pathogenesis and potential biomarkers for the diagnosis and treatment of MG, based on genetic and epigenetic studies. (Frontiers)
Insmed
- Company Mentions:
- Insmed will begin Phase I trials for its Duchenne muscular dystrophy (DMD) therapy, INS1201, in the first half of 2025. (India Times)